Key result
Globular adiponectin significantly decreased cerebral infarct size (p=0.009) and improved neurological deficit scores (p=0.028) in 8-week type 1 diabetic mice, but not in 2-week diabetic mice.
Why the study?
Does globular adiponectin reduce cerebral ischemic injury in type 1 diabetic mice?
Does globular adiponectin reduce cerebral ischemic injury in type 1 diabetic mice?
p-value: p=0.009
Globular adiponectin provides neuroprotection against cerebral ischemia/reperfusion injury in late-stage (8-week) but not early-stage (2-week) type 1 diabetic mice, dependent on dynamic AdipoR1 expression.
gAD neuroprotection may vary by T1DM duration in mice; leaves open translation to human diabetic stroke.
Recent studies have demonstrated that adiponectin (APN) attenuates cerebral ischemic/reperfusion via globular adiponectin (gAD). However, the therapeutic role of gAD in cerebral ischemic injury in type 1 diabetes mellitus (T1DM) remains unclear. Our results showed that gAD improved neurological scores and reduced the infarct volumes in the 8-week T1DM (T1DM-8W) mice, but not in the 2-week T1DM (T1DM-2W) mice. Moreover, the ischemic penumbra APN levels increased and peaked in T1DM-2W mice, and reduced to normal in T1DM-8W mice, while the APN receptor 1 (AdipoR1) expression change was the opposite. Administration of rosiglitazone in T1DM-2W mice up-regulated the expression of AdipoR1 and restored the neuroprotection of gAD, while intracerebroventricular injection of AdipoR1 small interfering RNA (siRNA) in T1DM-8W mice reversed it. Furthermore, the expression of p-PERK, p-IRE1 and GRP78 were increased whereas the expressions of CHOP and cleaved caspase-12 as well as the number of apoptotic neurons were decreased after gAD treatment in T1DM-8W mice. These beneficial effects of gAD were reversed by pretreatment with AdipoR1 siRNA. These results demonstrated a dynamic dysfunction of APN/AdipoR1 accompanying T1DM progression. Interventions bolstering AdipoR1 expression during early stages and gAD supplementation during advanced stages may potentially reduce the cerebral ischemic injury in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Song et al. (2015) studied Cerebral ischemia in type 1 diabetes mellitus (n=276). Globular adiponectin (gAD) vs. Vehicle (PBS) was evaluated on Cerebral infarct size 24 hours after ischemia/reperfusion in 8-week diabetic mice (p=0.009). Globular adiponectin significantly decreased cerebral infarct size (p=0.009) and improved neurological deficit scores (p=0.028) in 8-week type 1 diabetic mice, but not in 2-week diabetic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: